Dear all, This is indeed very sad. I concur with everyone. Ton was a very nice person, always open to listen to you and provide advice and support. II met with him a couple of times in the early 90ies and particularly in one formal meeting (probably in 1992) when he was heading Pharmacometry at FDA. He has been so supportive to my popPK/PD plans to support the filing of docetaxel (Taxotere) that when I got back in my company (Rhone Poulenc, now Sanofi) that the SVP of Regulatory asked me "what it is that you are doing? population PK???? Given such positive feedback from Tom (and FDA) I got full support to get the data and analysis done on time for the filing. Tom's support changed my life as well as the one of patients receiving Taxotere with the Boxed Warning about elevated hepatic enzymes (still in the US PI) and the dose adjustment in the EU SCP.
I will be indebted to him forever. René <https://www.avast.com/sig-email?utm_medium=email&utm_source=link&utm_campaign=sig-email&utm_content=webmail> Sans virus.www.avast.com <https://www.avast.com/sig-email?utm_medium=email&utm_source=link&utm_campaign=sig-email&utm_content=webmail> <#DAB4FAD8-2DD7-40BB-A1B8-4E2AA1F9FDF2> Le ven. 2 août 2024 à 20:56, Riley, Steve <steve.ri...@pfizer.com> a écrit : > Dear NM-Users, > > > > Regrettably, I am writing to let you know that Dr. Ludden passed away > Tuesday evening, 30JUL2024. > > I was able to get there over the weekend prior to visit him and his > family. > > During his wakeful moments we had some good scientific discussions. > > We talked a lot about NONMEM and how its functionality and utility has > expanded since he retired. He was pleased to hear about the changes. > > He was surrounded by family for the days leading up to the end. They were > all appreciative that I was able to get there and tell him (and them) how > much he meant to all of us and the impact he had on our careers. > > > > I think memories of Dr. Ludden were characterized perfectly by Marc > Gastonguay, “I am forever grateful for the positive impact that Tom had on > my life and career, not to mention the tremendous, although often > underappreciated, contributions he made to the disciplines of clinical > pharmacology and pharmacometrics. His humble brilliance will be missed and > fondly remembered.” > > > Steve Riley > > >
